XML 21 R12.htm IDEA: XBRL DOCUMENT
v3.23.3

Stockholder's Equity | 9 Months Ended
--- | ---
Sep. 30, 2023
Share-Based Payment Arrangement, Noncash Expense [Abstract] |
Stockholder's Equity | Stockholder's Equity (a) Stock Equity and Incentive Plan The Company recognizes stock-based compensation in accordance with the provisions of ASC Topic 718, Compensation-Stock Compensation. On June 8, 2022, at the Company's 2022 Annual Meeting of Stockholders, the stockholders of the Company approved an amendment and restatement of the Company’s current equity compensation plan to increase the number of shares of common stock reserved for issuance under the plan by 1,280 shares, from 4,800 shares to 6,080 shares (excluding rollover shares). Stock-based compensation expense was $558 and $1,103, excluding $1 and $6 of compensation charges related to our Amended and Restated 1996 Employee Stock Purchase Plan, or the ESPP, for the three months ended September 30, 2023 and 2022, respectively, and $1,408 and $2,663, excluding $25 and $32 of compensation shares related to the ESPP, for the nine months ended September 30, 2023 and 2022, respectively. As of September 30, 2023, there was $2,272 of total unrecognized compensation expense related to stock options, which is expected to be recognized over a weighted-average period of 2.66 years. As of September 30, 2023, there was $2,953 of total unrecognized compensation expense related to restricted stock awards, which is expected to be recognized over a weighted-average period of 2.52 years. Stock Options During the three months ended September 30, 2023, the Company issued 14 shares of common stock upon the exercise of stock options and received $113 as payment for the exercise price. No shares were surrendered to the Company to satisfy minimum tax withholding obligations. Additionally, during the three months ended September 30, 2023, no stock options were granted and 133 stock options expired, were canceled or were forfeited. During the nine months ended September 30, 2023, the Company issued 274 shares of common stock upon the exercise of stock options and received $2,480 as payment for the exercise price. No shares were surrendered to the Company to satisfy minimum tax withholding obligations. Additionally, during the nine months ended September 30, 2023, 317 stock options were granted and 564 stock options expired, were canceled or were forfeited. During the nine months ended September 30, 2022, 398 stock options were granted. The Company has historically estimated the fair value of each option grant on the date of grant using the Black-Scholes option-pricing model. The weighted average assumptions utilized to determine the fair value of options granted during the nine months ended September 30, 2023 and 2022 are as follows:
| Nine Months Ended September 30, |  |  |  |  |
| 2023 |  | 2022 |  |  |  |  |
Risk-free interest rate | 4.49 | % |  | 2.97 | % |  |  |  |  |
Expected volatility | 43.93 | % |  | 43.16 | % |  |  |  |  |
Expected life (in years) | 4.30 |  | 4.24 |  |  |  |  |
Dividend yield | 0 | % |  | 0 | % |  |  |  |  |
As of September 30, 2023, there were 1,230 options outstanding with a weighted average exercise price of $9.57 per share and 510 options exercisable with a weighted average exercise price of $9.56 per share. Restricted Stock During the three months ended September 30, 2023, 66 shares of restricted stock were granted with a weighted average grant date fair value of 8.75 per share and no shares of restricted stock were forfeited. Additionally, during the three months ended September 30, 2023, 7 shares of restricted stock vested, of which no shares of common stock were surrendered to the Company as payment by employees in lieu of cash to satisfy minimum tax withholding obligations in connection with the vesting of restricted stock. During the nine months ended September 30, 2023, 217 shares of restricted stock were granted with a weighted average grant date fair value of $9.49 per share and 72 shares of restricted stock were forfeited. Additionally, during the nine months ended September 30, 2023, 101 shares of restricted stock vested, of which no shares of common stock were surrendered to the Company as payment by employees in lieu of cash to satisfy minimum tax withholding obligations in connection with the vesting of restricted stock. As of September 30, 2023, the Company had no unvested outstanding options and no outstanding shares of restricted stock that were subject to performance-based or market-based vesting conditions. Common Stock Repurchase In the first quarter of 2023, the Company’s Board of Directors authorized the repurchase of a portion of executive common stock. The Company repurchased 23 shares of common stock held by executives at the Company to satisfy minimum tax withholding obligations in lieu of cash payment. No shares of common stock were repurchased during the twelve months ended December 31, 2022. (b) Employee Stock Purchase Plan The Company's ESPP affords eligible employees the right to purchase common stock, via payroll deductions, through various offering periods at a purchase price equal to 85% of the fair market value of the common stock on the first or last day of the offering period, whichever is lower. During the three months ended September 30, 2023 and 2022, 17 and 0 shares were issued under the ESPP plan, respectively. During the nine months ended September 30, 2023 and 2022, 17 and 22 shares were issued under the ESPP plan, respectively. The Company recorded compensation charges related to the ESPP of $1 and $6 for the three months ended September 30, 2023 and 2022, respectively, and $25 and $32 for the nine months ended September 30, 2023 and 2022, respectively. (c) Stock-Based Compensation Expense The following table presents stock-based compensation expense, including expense for the ESPP, in the Company's consolidated statements of operations for the three and nine months ended September 30, 2023 and 2022:
| Three Months Ended September 30, |  | Nine Months Ended September 30,
| 2023 |  | 2022 |  | 2023 |  | 2022
Cost of product sales | $ | 9 |  |  | $ | 333 |  |  | $ | 25 |  |  | $ | 468 |
Cost of service sales | 6 |  |  | 3 |  |  | 15 |  |  | 8 |
Research and development | 162 |  |  | 371 |  |  | 399 |  |  | 702 |
Sales, marketing and support | 63 |  |  | 14 |  |  | 160 |  |  | 225 |
General and administrative | 319 |  |  | 388 |  |  | 834 |  |  | 1,292 |
| $ | 559 |  |  | $ | 1,109 |  |  | $ | 1,433 |  |  | $ | 2,695 |
(d) Accumulated Other Comprehensive Loss (AOCL) Comprehensive income (loss) includes net income (loss), unrealized gains and losses from foreign currency translation, and unrealized gains and losses on available for sale marketable securities. The components of the Company’s comprehensive income (loss) and the effect on earnings for the periods presented are detailed in the accompanying consolidated statements of comprehensive (loss) income. The balances for the three months ended September 30, 2023 and 2022 are as follows:
| Foreign Currency Translation |  |  |  | Total Accumulated Other Comprehensive Loss |  |
Balance, June 30, 2023 | $ | (3,955) |  |  |  |  | $ | (3,955) |  |  |
Other comprehensive loss | (267) |  |  |  |  | (267) |  |  |
Net other comprehensive loss | (267) |  |  |  |  | (267) |  |  |
Balance, September 30, 2023 | $ | (4,222) |  |  |  |  | $ | (4,222) |  |  |
| Foreign Currency Translation |  |  |  |  |  | Total Accumulated Other Comprehensive Loss
Balance, June 30, 2022 | $ | (4,021) |  |  |  |  |  |  | $ | (4,021) |
Other comprehensive loss | (646) |  |  |  |  |  |  | (646) |
Net other comprehensive loss | (646) |  |  |  |  |  |  | (646) |
Balance, September 30, 2022 | $ | (4,667) |  |  |  |  |  |  | $ | (4,667) |
The balances for the nine months ended September 30, 2023 and 2022 are as follows:
| Foreign Currency Translation |  | Unrealized (Loss) Gain on Available for Sale Marketable Securities |  | Total Accumulated Other Comprehensive Loss
Balance, December 31, 2022 | $ | (4,098) |  |  | $ | (12) |  |  | $ | (4,110) |
Other comprehensive (loss) income | (124) |  |  | 12 |  |  | (112) |
Net other comprehensive (loss) income | (124) |  |  | 12 |  |  | (112) |
Balance, September 30, 2023 | $ | (4,222) |  |  | $ | — |  |  | $ | (4,222) |
| Foreign Currency Translation |  |  |  | Total Accumulated Other Comprehensive Loss
Balance, December 31, 2021 | $ | (3,409) |  |  |  |  | $ | (3,409) |
Other comprehensive loss | (1,258) |  |  |  |  | (1,258) |
Net other comprehensive loss | (1,258) |  |  |  |  | (1,258) |
Balance, September 30, 2022 | $ | (4,667) |  |  |  |  | $ | (4,667) |

X
- Definition The entire disclosure for share-based payment arrangement. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//718/tableOfContent Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (l) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_ShareBasedCompensationAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration